Aleksi Tornio

Methodology of drug-drug interactions studies: current state of the art

Aleksi Tornio is a medical specialist in clinical pharmacology working as a clinical lecturer at the Department of Clinical Pharmacology, University of Helsinki, Finland since 2011. He was a visiting post-doctoral scientist in the University of Dundee in 2016-2017 in the group of Professor Colin Palmer. His research focuses on drug-drug interactions and pharmacogenetics. He also serves as the secretary of the Finnish Society of Clinical Pharmacology.

Alexandra Aubry

New treatment options for resistent tuberculosis

Alexandra Aubry has been trained at the Medical school of Université Paris Diderot where she passed her MD Thesis (describing one of the largest cohort of M. marinum infections) in 1999. She started working on her PhD thesis on DNA gyrase in Mycobacterium tuberculosis in 2000 in the team of Vincent Jarlier, at the Université Pierre and Marie Curie (now Sorbonne-Université) in Paris and pursued this work during a postdoc in the group of Mark Fisher in London, an internationally well recognized expert in topoisomerases. In the meantime, she learned Medical Microbiology at the Bench in the Department of Bacteriology-Hygiene at Pitié-Salpêtrière hospital in Paris (head: Vincent Jarlier), where she became Assistant Professor (2000), Associated Professor (2006) and Professor (2016).
Alexandra Aubry works in the field of antibiotic resistance, especially focusing on mycobacteria and fluoroquinolones.
She is currently doing her research activity at the Cimi-Paris, Sorbonne-Université, in the team she leads “Emergence and Diffusion of Multiple Resistance against Antibiotics”. This team focuses on the mechanisms of emergence and diffusion of multiple drug resistance (MDR) in bacteria by using two models, (i) chromosome-born MDR in Mycobacterium tuberculosis (Mtb) and (ii) plasmid-born MDR in Enterobacteriaceae. Her group was pioneer in characterizing the enzymatic activities of mycobacterial DNA gyrases and determining the three-dimensional structure of M. tuberculosis DNA gyrase. She also recently filed a patent regarding new antituberculous drugs.

András Inotai

How to solve money gap to ensure patient access to pharmaceuticals in CEE counties

András Inotai PharmD, PhD, DrHabil is a graduate of Semmelweis Medical University in Budapest (PharmD, 2007), the Eötvös Loránd Science University in Budapest (Diploma in pharmaceutical policy and pharmacoeconomics, 2008), the Semmelweis University School of PhD Studies in Budapest (PhD in Pharmacoeconomics, 2011) and the Eötvös Loránd Science University in Budapest (Habilitation in Sociology, 2018). Dr. Inotai is a principal researcher of Syreon Research Institute and the Head of Pharmaceutical Policy Research. He has more than 12 years of research experience in pharmaceutical policy, pharmacoeconomics, health technology assessment and patient reported outcomes. He is also an assistant professor at Eötvös Loránd University (MSc in Health Policy, Finance and Analysis) leading the modules of Patient Reported Outcomes, Pharmaceutical policy and Pharmacoeconomics. Dr. Inotai was the president of ISPOR Hungary Chapter between 2014-15 and member of the ISPOR Central Eastern European Network Executive Committee (2013-2017). He was the co-editor of the ISPOR CEE Network Newsletter (2013-2017). He is author of 4 books, and more than 40 peer-reviewed scientific publications in health economics and pharmaceutical policy with a cumulative impact factor of 50.3.

Ann Langius-Eklöf

Smart phones provide smart patients

Ann Langius-Eklöf is a professor in nursing PhD, RN and leader of the research group I-CARE at the Division of Nursing. Head of Division of Nursing and responsible for the subject nursing and Deputy head of the Department of Neurobiology, Care Sciences and Society (NVS).
Her research focuses on the salutogenic perspective, which focuses on health, resources and subjective evaluations. Methodological and clinical studies on how patient reported outcomes such as quality of life, well-being, symptoms and satisfaction can be integrated in clinical care are performed. There are several individual factors influencing how a person perceives the situation in connection with a disease. One important factor is the person’s coping capacity defined by the concept Sense of Coherence (SOC). Sense of coherence reflects a person’s view of life on how comprehensible, manageable and meaningful life appears. The SOC scale is included as an important independent factor in the research studies. Ann Langius-Eklöf and her team have developed an interactive ICT-platform (an app-Interaktor) for symptom management and evaluate the effects concerning symptom burden, health-related quality of life, self-care, participation and recovery. The projects are based on their Participatory Care Model, which emphasizes on the integration of the person-centered perspective and the professional knowledge calling for a paradigm shift of how heath care is organized.

Ann Lykkegaard-Sorensen

Interprofessional approach for safer medication in psychiatry

Ann Lykkegaard Sørensen is a senior lecturer at the University College of Northern Denmark. She has carried out studies about errors in medication handling, inappropriate prescribing in psychiatry and most recently intercollaboration between physicians and nurses. Ann Lykkegaard Sørensen will present some perspectives on the importance of intercollaboration in medication safety.
Her background includes the following:
2010 – Master in Health Science from Aarhus University, Denmark
2010 – Lecturer at the Nursing Department at The University College of Northern Denmark
2016 – Senior lecturer
2017 – PhD

Anna-Karin Hamberg

Clinical use of pharmacokinetics - is Ctrough the answer to everything?

Anna-Karin Hamberg is a Pharmacist by training, and currently works as a clinical PK/PD-expert at the Department of Clinical Pharmacology, Uppsala University Hospital, Sweden. She received both her MSc in Pharmacy and PhD in Medical Sciences from Uppsala University. She has a long background as a regulatory expert in pharmacokinetics and pediatric clinical pharmacology, mainly from working as a pharmacokinetic assessor at the Swedish Medical Products Agency in Uppsala. But she has also served as a member of the Pediatric Committee (PDCO) at the European Medicines Agency (EMA), as a bioequivalence expert for WHO in Geneva and as a clinical pharmacologist at Roche in Basel. Her primary research interest is to develop and improve the hospitals therapeutic drug monitoring service through the integration of PK/PD-modeling and simulation into the clinic, sometimes referred to as model-informed precision dosing (MIPD).

Anne Spinewine

Prescribing in the frail elderly

Anne Spinewine graduated as a pharmacist (MPharm) at the Université catholique de Louvain (UCLouvain, Belgium) in 1999. She completed an MSc in clinical pharmacy, international practice and policy in 2001 (University of London), her PhD in 2006 and a master in hospital pharmacy in 2007 (UCLouvain).

She currently works half-time as the head of clinical pharmacy of a teaching hospital (CHU UCL Namur) and half-time as a professor in clinical pharmacy at UCL. She leads the clinical pharmacy research group at the Louvain Drug Research Institute (https://uclouvain.be/en/research-institutes/ldri/clinical-pharmacy-clip.html ). Her research focuses on the appropriate use of medicines in clinical practice, with a specific focus on appropriate prescribing in older people in different settings. Over the last 15 years, she has also significantly contributed to the development of clinical pharmacy practice and teaching in Belgium.

Bettina Ryll

New hope, new challenges - the introduction of IO in Melanoma, a patient perspective

Melanoma Patient Network Europe, Founder, Uppsala, Sweden
Dr. Ryll holds a medical degree from the Free University of Berlin, Germany, and a
PhD in Biomedical Sciences from University College London, UK. After losing her husband to Melanoma, she founded the Melanoma Patient Network Europe and developed a special interest in patient-centric clinical research, innovative trial designs and novel drug development concepts, such as MAPPS (medicines’ adaptive pathways to patients). Lately, she focuses on patient-relevant outcomes and sustainable healthcare models ensuring access to innovation for patients.
Dr. Ryll is involved in numerous initiatives promoting evidence-based advocacy. She
is fascinated by the enormous potential and capacity of patient networks to both
educate and support patients as well as to capture data at the primary data source,
the patients themselves, to generate evidence at a granularity level non-accessible to
outsiders. Between 2015 and 2018, Dr. Ryll chaired the ESMO-PAWG, the first time this position was held by a non-oncologist and was instrumental behind the development of the
advocacy track at annual ESMO conferences.

Björn Wettermark

How to measure drug utilization

Björn Wettermark, M.Sc.Pharm, PhD is employed by the regional health board of Stockholm, Sweden, currently acting as project leader responsible for implementing a new structure for knowledge management, i.e. guidelines, registries and quality improvement in the region. Björn is associate professor in pharmacoepidemiology at Karolinska Institutet with research focusing on various drug utilization topics such as prescribing quality indicators, international comparisons of drug utilization, evaluation of prescribing doctors´ adherence to guidelines and intervention studies to promote rational use of drugs. Other commitments include membership in national and regional strategic groups on medicine management, scientific advisor to the Swedish Medical Products Agency as well as past chair of the European Drug Utilization Research group, the European chapter of the International Society for Pharmacoepidemiology.

Caridad Pontes García

Targeting small populations: barriers to market access

Caridad Pontes is a medical specialist in clinical pharmacology, she has been working mainly on drug development and regulation in different settings, from pharmaceutical industry to
academy and administration. Since 2016 she is in charge of drug appraisal and therapeutic
positioning at the Catalan Health System.
As associated professor at the Department of Pharmacology, Therapeutics and Toxicology at
Universitat Autònoma de Barcelona since 2011, she is teaching Pharmacology and Clinical
Pharmacology at the Medical School. Her recent research has been focused on improving
methods for drug development in small populations, pragmatic trials and
pharmacoepidemiology in mental health.

Christoph Stein

New concepts in opioid analgesia

Christoph Stein was trained in Anesthesiology, Pain Medicine and Neuropharmacology. He has extensive background in basic, translational and clinical research, as well as in treatment of patients with acute and chronic pain. In 1990, his group discovered a “peripheral gate” at the source of pain generation by demonstrating that immune cell-derived opioid peptides silence sensory neurons carrying opioid receptors within inflamed tissue. This was the first morphological proof of opioid receptors on peripheral nerve terminals, and the first example of neuro-immune interactions modulating pain. Soon thereafter, they confirmed the relevance of such peripheral opioid actions in clinical studies. Subsequently, his group characterized the expression, regulation, cellular trafficking, tolerance development and endogenous activation of peripheral opioid receptors in animal models and in patients. In 2017, they published an innovative concept for the design of non-addictive analgesic drugs, based on computational modeling of disease-specific opioid receptor conformations.

Cornelis Kramers

Polypharmacy: acting on the cutting edge of safety, efficacy and compliance

Dr Cornelis Kramers is internist clinical pharmacologist and professor of medication safety at Radboud university medical center, Nijmegen, the Netherlands. He also works in the hospital pharmacy of the CWZ hospital in Nijmegen. He has performed research on medication safety both inside and outside the hospital. He is also co-founder of the Pharmacotherapy End Test, which has to be taken by all medical students in the Netherlands in order to improve medication safety.

Dario Cattaneo

Antiinfectives in intensive care

Dr Cattaneo granted Pharmacy degree and post-degree specialization in Pharmacology (University of Milan) and PhD degree (Open University, UK). From 1997 to 2008 he was employed at the Mario Negri Institute for Pharmacological Research, Bergamo, as Head of the Unit of Pharmacology and Pharmacogenetics. Actually, Dr Cattaneo is employed at the Unit of Clinical Pharmacology, Luigi Sacco University Hospital (Milan). From 2012 he is also appointed as assistant professor of Pharmacology, Faculty of Medicine (University of Milan). Dr Cattaneo is Author of nearly 180 scientific articles published in peer-review journals (H-index 35, more than 4500 citations).

David Webb

Health economics: big ideas from a small country

Professor David Webb is a clinical pharmacologist who has undertaken basic, translational and clinical research for over 30 years in pursuit of developing safe and effective medicines for the treatment of hypertension. A Fellow of the UK Academy of Medical Sciences and Royal Society of Edinburgh, David holds the Christison Chair of Therapeutics and Clinical Pharmacology at the University of Edinburgh. He hosted the EACPT Congress in Edinburgh in 2009.

David Webb has been Chair of the Scottish Medicines Consortium, President of the BPS, and Chair of the Clinical Division of IUPHAR, for whom he will be President for the World Congress of Basic and Clinical Pharmacology in 2022. He is Vice Chair of the MHRA Board and has a major interest in drug development, regulation and pricing.

Denis O’Mahony

STOPP/START decision support for elderly prescribing

Prof. Denis O’Mahony, MD, FRCPI, FRCP (UK), has worked at senior faculty level in the Department of Medicine at the University College of Cork (Ireland) since 2005. He previously worked as Senior Lecturer in Geriatric Medicine at the University of Birmingham, UK, from 1995 to 1999. He worked as Consultant Physician in Geriatric Medicine to Cork University Hospital from 1999 to 2004. Since the mid-1990s, most of his research has focused on adverse pharmacotherapy in older people and its prevention. All of his research in recent years has focused on novel methods for optimizing pharmacotherapy in older people with multi-morbidity and its associated polypharmacy. He has collaborated closely with Prof. Stephen Byrne, Head of the UCC School of Pharmacy, in joint research work on pharmacotherapy optimization in older people since 2006.
Prof. O’Mahony is the original inventor and principal developer of STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria. STOPP was designed to detect potentially inappropriate medications (PIMs), START was designed to detect potential prescribing omissions (PPOs).
Prof. O’Mahony has over 170 peer-reviewed publications, details of most of which may be found at the following webpage: http://research.ucc.ie/profiles/C012/denisomahony

Gerd Lärfars

Horizon scanning frontiers

Gerd Lärfars is Ass prof, M.D, specialist in hematology and internal medicine

Her present positions are:

Head of the Pharmaceutical unit at Region Stockholm Healthcare administration

Chairman of The Drug and Therapeutic Committé of Region Stockholm

Chairman of the national board of New Therapies (NT-rådet)

Gonzalo Calvo

Drug regulation in the 2020s - an academic perspective

Gonzalo Calvo is Senior Consultant and Head of the Clinical Pharmacology Department at the Hospital Clinic of Barcelona. He has a vast regulatory experience, having served as member of the EMA- Committee for Human Medicinal Products (CHMP) from 2002 to 2011. For more than 10 years he chaired the CHMP Cardiovascular Working Party, the EMA policy-making body in cardiovascular diseases from 2000 to 2011. He has been rapporteur of more than 80 applications for authorization of new drugs and has actively contributed to the development of regulations on biosimilars in Europe. He is the Past-Chair of the European Association for Clinical Pharmacology and Therapeutics (EACPT). On 24 September 2013 he was elected as co-chair of the EMA-Healthcare Professionals Working Party (HCPWP), being re-elected on 21 September 2016.

Harry Sokol

Gut microbiota - a new actor in pharmacology?

Harry Sokol is Professor in the Gastroenterology department of the Saint Antoine Hospital (APHP, Paris, France) and is the head of the Gut Microbiota and Immunity lab (INSERM CRSA UMRS 938, Sorbonne Université, Paris and INRA Micalis). Harry Sokol is an internationally recognized expert in Inflammatory Bowel Disease (IBD) and in gut microbiota fields. He has published over 170 papers on these topics in major journals (including Gut, Gastroenterology, Cell Metabolism, Cell Host & Microbe, Nature communication, Nature Medicine). His work on the role of the gut microbiota in IBD pathogenesis led to landmark papers describing the IBD-associated dysbiosis (imbalance in gut microbiota composition) and the role of the pivotal commensal bacteria Faecalibacterium prausnitzii in gut homeostasis and in IBD. Currently, his work focuses on deciphering the gut microbiota-host interactions in health and diseases (particularly IBD), in order to better understand their role in pathogenesis and develop innovative treatments. Harry Sokol is exploring particularly the role of the microbiota in tryptophan metabolism for which he is recipient of an ERC grant. Beside basic science, he is also involved in translational research. He is the current president of the French group of fecal microbiota transplantation, he coordinated a pilot randomized control trial evaluating fecal microbiota transplantation in Crohn’s disease and he is currently coordinating a phase III nationwide randomized control trial evaluating fecal microbiota transplantation in ulcerative colitis.

Henk Jan Guchelaar

Clinical implementation of pharmacogenetics

Prof. Dr. Henk Jan Guchelaar has completed his education Pharmacy (cum laude) and doctoral research at Groningen University, the Netherlands. The title of his doctoral thesis (1993) is ‘Modulation of cisplatin activity and toxicity; changing the drug or changing the target’. Guchelaar performed a clinical orientation at the New England Medical Centre Hospital in Boston, USA. After his graduation, Guchelaar further specialised in hospital pharmacy and clinical pharmacology at the University Medical Centre Groningen. In 2003, he was appointed professor Clinical Pharmacy at the LUMC, and in 2008 of the LACDR, University of Leiden. The title of his inaugural lecture was ‘(Bij)werking begrepen’.
Henk-Jan Guchelaar is professor Clinical Pharmacy at both the Leiden University Medical Center (LUMC) and the faculty of Math & Natural Sciences of the University of Leiden (LACDR). He is head of the department of Clinical Pharmacy & Toxicology of the LUMC and program leader of the research program ‘Personalised Therapeutics’. He is also director of the Leiden University research profile ‘Translational Drug Discovery and Development’ and founder of the Master Pharmacy. In addition, he coordinates a European Horizon 2020 project about implementation of pharmacogenetics in routine health care; Ubiquitous Pharmacogenomics (U-PGx). Guchelaar is chair of the board of division 4 of the LUMC. He is also clinical trainer Clinical Pharmacology and deputy clinical trainer Hospital Pharmacy.
Since more than 20 years, Henk-Jan Guchelaar performs research in the field of ‘Personalised Therapeutics’ with a strong focus on pharmacogenetics and oncology.
He has published over 300 scientific publications.

Howard Lee

Polypharmacy in Korea

Dr. Howard Lee is the Founder and Director of the Center for Convergence Approaches in Drug Development (CCADD), Seoul National University. Dr. Lee serves as a Professor at the Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University. Dr. Lee is also appointed at Seoul National University College of Medicine and Hospital, affiliated with the Department of Clinical Pharmacology and Therapeutics. Dr. Lee previously served as Head of Global Strategy and Planning, Clinical Trials Center, SNUH. Dr. Lee is currently the Chair of the Graduate Program in Clinical Pharmacology, Seoul National University. In addition, Dr. Lee is the Chair, Radiation Biomedical Science, Graduate School of Convergence Science and Technology, Seoul National University.

Dr. Lee is a board-certified physician in Family Medicine and Clinical Pharmacology and holds a PhD in Epidemiology. Dr. Lee completed a fellowship in Clinical Pharmacology at the Center for Drug Development Science (CDDS), Department of Pharmacology, Georgetown University School of Medicine in Washington DC, USA, where he subsequently served as an Assistant Professor of Medicine and eventually became Director after CDDS has joined the University of California San Francisco in association with the School of Pharmacy. Dr. Lee also had served as faculty in two other US-based universities including the University of California San Francisco and the University of Pittsburgh.

Dr. Lee’s professional career consists of an interesting mix of academia, industry, and government. Before he went to the US, Dr. Lee had a 5-year real-world experience in clinical drug development at two pharmaceutical companies as Medical Director. Dr. Lee also was a Guest Researcher at the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration.

Dr. Lee was the co-principal investigator for clinical pharmacology of the Washington Obstetric Pharmacology Research Unit Network grant (NIH HD-03-017) affiliated with Georgetown University Medical Center. Dr. Lee also served as a co-investigator of the Collaborative Pediatric Pharmacology Research Unit Network grant (NIH HD-03-001). Dr. Lee was the principal investigator of the Merck Foundation Grant, entitled “A Systematic Policy Analysis to Identify Key Strategies for Implementing Good Review Practices into the Korea Food and Drug Administration”.

Since returning to Korea in late 2012, Dr. Lee has served as the principal investigator in >19 clinical pharmacology studies including eight first-in-human studies. Furthermore, Dr. Lee has spearhead the introduction of the Accelerator Mass Spectrometry (AMS)-enabled exploratory microtracing study in early clinical drug development studies to the Korean biopharmaceutical R&D sector. Dr. Lee has received three government grants in microtracing. The most recent one (2017) was to expand the technology to the development of a new biologic first time, which has not been tried by anyone in the world.

Dr. Lee is well-versed in pharmacometrics, clinical trials design, drug development science, and drug regulations (Korea and the US). Dr. Lee’s current research interests are first-in-human studies of new drugs including biologics, AMS-based microdosing and microtracing studies, pharmacokinetic-pharmacodynamic modeling, regulatory issues related to biosimilar products, and, lastly but not the least, artificial intelligence to streamline clinical drug development practices.

Jenny Kindblom

Pediatric clinical trials and their pitfalls

Jenny Kindblom is a specialist in clinical pharmacology with ten years’ experience from the Department of Clinical Pharmacology at Sahlgrenska University Hospital. Her main interest is pediatric clinical pharmacology. Since 2016 she is the medical director of the Pediatric Clinical Research Center, PCRC, at Queen Silvia Children´s Hospital at Sahlgrenska University Hospital. She is also an associate professor at the Institute of Medicine, the Sahlgrenska Academy.

Jonas Oldgren

Innovative ways of performing clinical trials

Jonas Oldgren is Professor of Coagulation Research at Uppsala University, Senior consultant in Cardiology at Uppsala University Hospital, and Executive director of Uppsala Clinical Research Center (UCR), a non-profit academic clinical research organization within Uppsala University and Uppsala University Hospital. Dr Oldgren has been investigator, national coordinator, and more recently executive steering committee member and/or coordinating investigator in several large-scale randomized clinical trials in cardiovascular medicine, e.g. RE-LY, RE-DEEM, EMANATE, RE-DUAL PCI, SPIRRIT-HFpEF, SCOREd, TIMING, and ABC AF, and serves in data safety monitoring boards of on-going multinational clinical trials. Dr Oldgren was a member of the task force for the 2016 European Society of Cardiology Atrial Fibrillation Guidelines, participated in the writing committee for European Heart Rhythm Association NOAC Practical guide 2013, 2015 and 2018, and has published more than 100 papers in peer-reviewed journals.

Markus Meyer

How to measure drug exposure

Markus Meyer holds a PhD in Metabolism of Methylenedioxy Designer Drugs from the Department of Experimental and Clinical Toxicology, Saarland University (Germany). He has previously worked as Associate Professor at Karolinska Institutet and at Heidelberg University.
Since 2016, he is working as Full Professor and Chair of the Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology, Center for Molecular Signaling (PZMS), at Saarland University.
He is also head of the 24/7 ClinTox laboratory of the Saarland University.
Markus Meyer has received several academic distinctions and awards, among others the “Young Scientists Award” (in 2008), Habilitation and Venia Legendi for Pharmacology and Toxicology (in 2014) and the “Victor Armstrong Award” (in 2017).

By attending Markus Meyer’s workshop on “How to measure drug exposure“, the learner will be able to describe strategies and workflows to analyze drugs and drugs of abuse for answering questions in the context of clinical toxicology.

Martina Schüssler-Lenz

10 years of Advanced Therapy Regulation in the European Union

Dr. Martina Schüssler-Lenz is the Chair of the Committee for Advanced Therapies (CAT) of the European Medicines Agency’s (EMA). The CAT is the committee responsible for evaluating the quality, safety and efficacy of marketing authorisations of cell and gene therapies (Advanced Therapy Medicinal Products, ATMPs).
Since 2005, she is working as M.D. at the Paul-Ehrlich Institute in the Section Advanced Therapies and Tissue Preparations. Martina is responsible for advising companies on drug development issues, reviewing clinical trials and marketing authorisations.
Overall, Martina has 30 years of professional experience. She received her medical degree in Germany at Mainz University. She completed an Internal Medicine residency, is board certified in internal medicine and worked many years in Hematology/Medical Oncology. Based on a grant from the German Research Council DFG she moved on to New York for a postdoctoral fellowship in tumor biology and immunology at the Memorial Sloan Kettering Cancer Center, followed by a fellowship at the Instituto Municipal de investigacion Medica in Barcelona, Spain.
She has been a member of the EMA Committee for Advanced Therapies for many years and was elected as its chairperson in February 2017.
Her scientific and regulatory work has resulted in several (co-)authorships in scientific journals, as for example recently the “Clinical development of CAR-T cells – challenges and opportunities in translating innovative treatment concepts” in EMBO Molecular Medicine.

Matt Doogue

Electronic prescribing or similar?

A/Prof Matt Doogue

Department of Medicine University of Otago-Christchurch & Clinical Director, Department of Clinical Pharmacology, Canterbury District Health Board, New Zealand

Matt Doogue is a clinical pharmacologist passionate about applying clinical pharmacology principles to patient care.  He is also an endocrinologist working in a busy acute general medicine service. His interests include therapeutic drug monitoring, adverse drug reactions, clinical decision support and quality use of medicines.

Nicolas Picard

The use of social media in CPT teaching

Prof. Nicolas Picard leads a thematic group on digital pedagogy at the international francophone society of medical education (https://www.sifem.net/fr/numerique-pedagogie). He is a pharmacist, professor of pharmacology (head of the pedagogical department at the Faculty of Pharmacy) at Limoges University (France) and a hospital pharmacologist at Limoges University Hospital. Before joining the faculty of Pharmacy, he taught pharmacology at the faculty of Medicine, the institute of nursing and the school of midwifery between 2006 and 2012. In 2016, he joined a department on digital education in Health sciences (www.duenes.fr) at Limoges University with the objective of promoting the use of digital for pedagogy in pharmacy and its interface with the medical or paramedical sciences. He is particularly attached to the notion of “blended e-learning”, a hybrid principle combining face-to-face and digital activities. He is involved in different academic project related to (i) the development of interactive digital activities offered during lectures, (ii) student peer-evaluation, (iii) the use of in-situ and virtual simulation in pharmaceutical sciences, and (iv) the use of social networks to disseminate academic knowledge.

Ole Petter Ottersen

Global health research and education in Europe - how can clinical pharmacology contribute?

Ole Petter Ottersen has been President of Karolinska Institutet since August 2017, and previously served as President of the University of Oslo (2009-2017).
As a neuroscientist, physician and academic leader, Ottersen has held numerous positions of trust. Between 2013 and 2015, he was head of the Norwegian Association of Higher Education Institutions and of the Nordic University Association.

Ottersen served as chairman of the board for Norway’s National Program for Functional Genomics (2003-2007), as director of Norway’s Centre of Excellence in Molecular Biology and Neuroscience (2002-2009) and as coordinator of the Nordic Centre of Excellence in Molecular Medicine (2005-2009). He has also coordinated two projects under the EU Framework Program and was the panel leader for European Research Council Advanced Grants (2008-2012). He is currently the panel leader for ERC Synergy Grants.

In recent years, he has been engaged in global health – much inspired by his experiences as Chair of the Lancet-University of Oslo Commission on Global Governance for Health (2011-2014). The Commission examined the political determinants of health and produced the 2014 report, “The Political Origins of Health Inequity: Prospects for Change” that preceded the publication of UN’s Agenda 2030. He currently serves as a board member of the African Population and Health Research Center (APHRC) based in Nairobi.

Between 2006 and 2009, Ottersen was Chief Editor of Neuroscience, the official journal of the International Brain Research Organization, and has also served on numerous boards and prize committees, including the Kavli Prize Committee in Neuroscience and the Thon Foundation Advisory Board.

At the University of Oslo, Ottersen was Dean of Science within the medical faculty (2000-2002) and has taught medical students, physiotherapists and postgraduate students since 1976.

Olof Breuer

Clinical use of pharmacokinetics - is Ctrough the answer to everything?

Dr Olof Breuer, MD, specialist in Clinical Pharmacology with PhD in Clinical Biochemistry, is employed at the Clinical Trials Unit, Dept of Clinical Pharmacology, Karolinska University Hospital. He has more than 15 years of experience from preclinical and clinical work within big and small pharmaceutical companies, where he has held positions as principal scientist, project manager, and director of Clinical Pharmacology. Dr Breuer’s core area of expertise is within translational sciences, in the transition between animal and man, and early clinical development (phase I-II). He routinely utilizes modelling and simulation techniques to facilitate study design and data evaluation.

Paul Hjemdahl

Dual or triple antithrombotic therapy - is two company and three a crowd?

Paul Hjemdahl, MD, PhD, is Senior professor in Clinical pharmacology (Karolinska Institutet) and consultant (Karolinska University Hospital). Previous head of department at the Karolinska Hospital. Fellow of the European Stociety of Cardiology (FESC) and the American Heart Association (FAHA). Research mainly in the cardiovascular field with studies on sympatho-adrenal function, hypertension, stable angina (APSIS study), diabetes, platelets and antiplatelet treatment, and anticoagulant treatment in atrial fibrillation. More than 300 original research articles and more than 100 overviews, Editorials and Book Chapters. Extensive work with research ethics at the national and regional level, as well as Drug and Therapeutics Committee work, especially with cardiovascular issues.

Stéphane Laurent

Update on treating hypertension

Stéphane Laurent is Emeritus Professor of Pharmacology in the Paris Descartes Medical School.
He was head of the Department of Clinical Pharmacology in the Hôpital Européen Georges Pompidou in Paris between 2008 and 2018, and head of INSERM U 970, team 7 in the Paris Cardiovascular Research Center (PARCC) between 2009 and 2018.
Professor Laurent has served as President of the European Society of Hypertension (ESH) (2007-2009), President of the ARTERY Society (2010-2012), and President of the French Society of Hypertension (2001-2002).
He is the co-author of the 2007, 2013 and 2018 ESH-ESC Guidelines for the management of Hypertension, and the 2009 ESH document on the reappraisal of hypertension guidelines. He is the author of over 400 referenced articles and 20 chapters in books.
His “h” index is 73 (Web of Science) with 15 “highly cited” papers, and the total number of citations of his articles is higher than 35,643 (Web of Science). Google Scholar’s H index is 84 with 66,659 citations.
Professor Laurent has delivered more than 350 invited lectures at international venues.

Sylvie Laporte

Meta-epidemiological studies to detect, quantify and adjust for bias in open-label trials

Sylvie Laporte is an assistant professor at the University Hospital of Saint-Etienne (France) since 2003, teaching physicians, pharmacists and statisticians. She is Head of Department of Clinical Pharmacology and a Member of the INSERM UNIT Sainbiose. Sylvie Laporte has a post-doctoral degree from Saint-Etienne University. Her field of research include clinical research on anticoagulants, meta-epidemiology and meta-analysis and meta-regression of pharmacological, clinical and epidemiological studies. She has experience of several multicenter trials (steering committee, data safety monitoring board, methodology, statistical analysis) and congress and meeting organization. She also has several national and European assignments, such as President of the French Society of Pharmacology and Therapeutics, Member of the National University Board on Pharmacology and Member of the Directorial Board of the University of Saint-Etienne.

Tim Nicholson

New targets in psychopharmacology

Dr Tim Nicholson is a Clinical Senior Lecturer at the Institute of Psychiatry Psychology & Neuroscience (IoPPN), King’s College London. He is also an Honorary consultant Neuropsychiatrist at the South London and Maudsley NHS Foundation Trust. He runs a specialist clinic for Functional Neurological Disorder (FND) at the Maudsley Hospital.

Tim trained briefly in neurology at the National Hospital for Neurology & Neurosurgery at Queen square before training fully in psychiatry and then neuropsychiatry at the Maudsley Hospital / IoPPN in South London.  He did his PhD, funded by the UK Medical Research Council (MRC), in FND looking at the role of stressful life events that might precipitate episodes of paralysis and used other methods such as neuroimaging (both structural and functional MRI scans) and neuropsychological testing to investigate the possible mechanisms of FND. He continues to be interested in the biological basis of FND symptoms.

He is now funded by the UK National Institute of Health Research (NIHR) running a series of randomised controlled trials (RCTs) of transcranial magnetic stimulation (TMS) for FND causing limb paralysis/weakness, with linked studies investigating how TMS might work. He is also involved in developing and standardising outcome measures for FND both for use in research & clinical practice and has set up an international collaboration of 40 researchers from 15 countries (the first such large scale international research collaboration of any sort for FND) to work together on this project.

You can find a list of his published research articles HERE.

Address:   Section of Cognitive Neuropsychiatry (PO68), Institute of Psychiatry Psychology & Neuroscience, De Crespigny Park, London SE5 8AF

Job Title:  Clinical Senior Lecturer & Honorary Consultant Neuropsychiatrist

Qualifications: MBBS, BSc, MSc, PhD, MRCP, MRCPsych

Urs Meyer

2019 Lifetime Achievement Award

The EACPT is delighted to announce that the 2019 Lifetime Achievement Award of the European Association of Clinical Pharmacology and Therapeutics will go to Professor Urs Meyer from Switzerland.

The Award, which includes the EACPT silver medal, will be presented to Professor Meyer during the next EACPT congress in Stockholm, where he will also as an invited speaker present the lecture: “Therapeutic Lessons from Human Individuality”

Viktor Hlaváč

Pharmacogenetics of cancer chemoresistance

Viktor Hlaváč is a junior scientist at a Toxicogenomics Department at National Institute of Public Health in Prague, Czech Republic since 2010. Viktor Hlaváč graduated at the Faculty of Science of Masaryk University in Brno in Czech Republic in 2005 in molecular biology and genetics. In 2017, he finished his PhD at the Third Faculty of Medicine, Charles University in Prague. Viktor Hlaváč is also a member of Laboratory of Pharmacogenomics in Biomedical Center in Pilsen (Faculty of Medicine in Pilsen, Charles University) since 2014.

The topic of his research is focused mainly on pharmacogenomics of solid cancers, e.g. breast, pancreatic and colorectal cancer and the chemoresistance of tumors. Viktor Hlaváč has his expertise in gene expression studies and next-generation sequencing. Among others, he deals with discovery of biomarkers of chemoresistance and prognosis of breast cancer patients.

Violeta Stoyanova-Beninska

Targeting small populations: drug designation and other regulatory challenges

Violeta Stoyanova-Beninska is currently working at the Medicines Evaluation Board, The Netherlands. In September 2018 Violeta has been elected as Chair of the Committee for Orphan Medicinal Products at the European Medicines Agency, of which she was a member from the Netherlands in the past 6 years. She was also Chair of the National Scientific and Regulatory Advice at MEB and member of the Scientific Advice Working party at EMA. Violeta Stoyanova is supervisor of PhD students, guest lecturer at Dutch universities, and she is involved in Regulatory Science research related to rare diseases, personalised medicine, psychiatry, neurology and human genetics.
Before moving to the regulatory area (2007), Violeta has been working in research and diagnostics in the field of clinical and molecular genetics (UHOG, ICGEB, Erasmus MC), and teaching and supervising medical students and PhDs, with main focus on monogenic disorders, cancer and epigenetics.